Monoclonal gammopathy
MONDO:0004960A condition characterized by the abnormal presence of monoclonal immunoglobulins in the blood or urine.
68 clinical trials for this condition and its sub-types, 24 tagged with Monoclonal gammopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Monoclonal gammopathy
-
Monoclonal paraproteinemia disease 2 trials
-
Can a multiple myeloma drug shield the kidneys in MGRS?
Disease control OngoingThis phase 2 trial tests whether isatuximab, an antibody drug already approved for multiple myeloma, can improve kidney function in people with monoclonal gammopathy of renal significance (MGRS). MGRS is a condition where abnormal proteins damage the kidneys. Participants receive…
Phase 2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could your next stem cell recovery happen at home?
Disease control OngoingThis study looks at whether people with plasma cell disorders can safely recover from an autologous stem cell transplant at home instead of in the hospital. Researchers want to see if home recovery is practical, reduces infections, and keeps patients satisfied. About 91 adults ag…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New antibody could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 125 people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove those protein deposits. The goal is to see if it helps people live …
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug aims to clear amyloid clumps and save hearts
Disease control OngoingThis phase 3 trial tests whether CAEL-101, an antibody that removes abnormal protein deposits from organs, can help people with AL amyloidosis live longer and avoid heart-related hospital stays. About 281 participants who have not yet received treatment for their plasma cell diso…
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…
Phase 1/2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can a cancer drug stop myeloma before it starts?
Disease control OngoingThis phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase 2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Laser light shows promise for rare nerve pain
Symptom relief By invitation onlyThis study tests whether photobiomodulation (low-level laser therapy) can reduce pain and disability in people with anti-MAG neuropathy, a rare nerve condition. Ten participants will receive 16 laser sessions over six weeks. Researchers will measure changes in disability, pain, a…
Sponsor: Centre Hospitalier de Cornouaille • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC